Bausch Health Files 8-K

TL;DR

Bausch Health filed an 8-K on 12/12/25. Details TBD.

AI Summary

Bausch Health Companies Inc. filed an 8-K on December 12, 2025, reporting other events and financial statements. The company, formerly known as Valeant Pharmaceuticals International, Inc. and BIOVAIL Corp, is incorporated in British Columbia, Canada, and its fiscal year ends on December 31st. The filing does not contain specific financial figures or details about the 'Other Events' beyond its classification.

Why It Matters

This 8-K filing indicates that Bausch Health Companies Inc. has made a regulatory submission to the SEC, which could contain material updates about the company's operations or financial status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not, on its own, indicate any immediate or significant risks.

Key Players & Entities

• Bausch Health Companies Inc. (company) — Registrant
• Valeant Pharmaceuticals International, Inc. (company) — Former Company Name
• BIOVAIL Corp (company) — Former Company Name
• December 12, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $2,802,125,000 — release announcing that it allocated a $2,802,125,000 tranche (the "Replacement Term Loans")

Filing Documents

• dp238710_8k.htm (8-K) — 25KB
• dp238710_ex9901.htm (EX-99.1) — 8KB
• image_001.jpg (GRAPHIC) — 3KB
• 0000950103-25-016089.txt ( ) — 203KB
• bhc-20251212.xsd (EX-101.SCH) — 3KB
• bhc-20251212_lab.xml (EX-101.LAB) — 33KB
• bhc-20251212_pre.xml (EX-101.PRE) — 22KB
• dp238710_8k_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. Bausch + Lomb Credit Agreement Refinancing On December 12, 2025, Bausch + Lomb Corporation ("Bausch + Lomb"), a subsidiary of Bausch Health Companies Inc. (the "Company"), issued a press release announcing that it allocated a $2,802,125,000 tranche (the "Replacement Term Loans") of new term B loans, the proceeds of which will be used to refinance all of its outstanding term B loans due 2031 (the "Third Amendment Term Loans") and its outstanding term B loans due 2028 (the "First Incremental Term Loans"). The applicable margin is anticipated to be (i) 3.75% per annum for Replacement Term Loans with an interest rate determined by reference to term SOFR and (ii) 2.75% per annum for Replacement Term Loans with an interest rate determined by reference to the alternate base rate; the margin applicable to the Replacement Term Loans represents a 0.50% per annum reduction for the Third Amendment Term Loans and a 0.25% per annum reduction for the First Incremental Term Loans. The Replacement Term Loans will mature on January 15, 2031, which is same maturity date as the Third Amendment Term Loans and which represents a maturity extension of the First Incremental Term Loans from September 29, 2028. The foregoing transactions are anticipated to close in the first quarter of 2026; however, there can be no assurances that Bausch + Lomb will be able to complete the foregoing transactions on the terms described above or at all. A copy of the press release issued by Bausch + Lomb related to the Replacement Term Loans is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial

Item 9.01 Financial (d) Exhibits Exhibit Number Description 99.1 Press Release of Bausch + Lomb Corporation, dated December 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

Signatures

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BAUSCH HEALTH COMPANIES INC. By: /s/ Jean-Jacques Charhon Name: Jean-Jacques Charhon Title: Executive Vice President, Chief Financial Officer Date: December 12, 2025

View Full Filing

View this 8-K filing on SEC EDGAR